Back to Browse Journals » Clinical Interventions in Aging » Volume 2 » Issue 4

The many faces of testosterone

Authors Jerald Bain

Published 15 January 2008 Volume 2007:2(4) Pages 567—576


Jerald Bain

Department of Medicine, Department of Obstetrics and Gynecology, University of Toronto, Ontario, Canada; Division of Endocrinology and Metabolism, Mount Sinai Hospital, Toronto, Ontario, Canada

Abstract: Testosterone is more than a “male sex hormone”. It is an important contributor to the robust metabolic functioning of multiple bodily systems. The abuse of anabolic steroids by athletes over the years has been one of the major detractors from the investigation and treatment of clinical states that could be caused by or related to male hypogonadism. The unwarranted fear that testosterone therapy would induce prostate cancer has also deterred physicians form pursuing more aggressively the possibility of hypogonadism in symptomatic male patients. In addition to these two mythologies, many physicians believe that testosterone is bad for the male heart. The classical anabolic agents, 17-alkylated steroids, are, indeed, potentially harmful to the liver, to insulin action to lipid metabolism. These substances, however, are not testosterone, which has none of these adverse effects. The current evidence, in fact, strongly suggests that testosterone may be cardioprotective. There is virtually no evidence to implicate testosterone as a cause of prostate cancer. It may exacerbate an existing prostate cancer, although the evidence is flimsy, but it does not likely cause the cancer in the first place. Testosterone has stimulatory effects on bones, muscles, erythropoietin, libido, mood and cognition centres in the brain, penile erection. It is reduced in metabolic syndrome and diabetes and therapy with testosterone in these conditions may provide amelioration by lowering LDL cholesterol, blood sugar, glycated hemoglobin and insulin resistance. The best measure is bio-available testosterone which is the fraction of testosterone not bound to sex hormone binding globulin. Several forms of testosterone administration are available making compliance much less of an issue with testosterone replacement therapy.
Keywords: testosterone, androgens, male hypogonadism, anabolic steroids

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Readers of this article also read:

The durability of sitagliptin in elderly patients with type 2 diabetes

Hsieh CJ, Shen FC

Clinical Interventions in Aging 2014, 9:1905-1911

Published Date: 7 November 2014

Predicting adverse drug reactions in older adults; a systematic review of the risk prediction models

Stevenson JM, Williams JL, Burnham TG, Prevost AT, Schiff R, Erskine SD, Davies JG

Clinical Interventions in Aging 2014, 9:1581-1593

Published Date: 19 September 2014

Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma

Graf N, Li ZL, Herrmann K, Weh D, Aichler M, Slawska J, Walch A, Peschel C, Schwaiger M, Buck AK, Dechow T, Keller U

OncoTargets and Therapy 2014, 7:789-798

Published Date: 23 May 2014


Cárdenas WH, Mamani JB, Sibov TT, Caous CA, Amaro E Jr, Gamarra LF

International Journal of Nanomedicine 2012, 7:5107-5108

Published Date: 21 September 2012

Novel drug-eluting stents in the treatment of de novo coronary lesions

Davide Capodanno, Fabio Dipasqua, Corrado Tamburino

Vascular Health and Risk Management 2011, 7:103-118

Published Date: 25 February 2011

Aripiprazole for late-life schizophrenia

Jeffrey Rado, Philip G Janicak

Clinical Interventions in Aging 2010, 5:253-258

Published Date: 30 August 2010

Eggshell membrane: A possible new natural therapeutic for joint and connective tissue disorders. Results from two open-label human clinical studies

Kevin J Ruff, Dale P DeVore, Michael D Leu, Mark A Robinson

Clinical Interventions in Aging 2009, 4:235-240

Published Date: 18 May 2009

Candesartan in heart failure

Toni L Ripley, Jennifer S Chonlahan, Robin E Germany

Clinical Interventions in Aging 2006, 1:357-366

Published Date: 15 January 2007

Pharmacologic interventions in aging hair

Ralph M Trüeb

Clinical Interventions in Aging 2006, 1:121-129

Published Date: 15 June 2006